APRE Aprea Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: APRE

Price (delayed)

$3.6103

Market cap

$13.47M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$75.13

Enterprise value

-$17.52M

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor ...

Highlights
The debt has dropped by 100% year-on-year
Aprea Therapeutics's net income has increased by 3.2% QoQ
The equity has contracted by 39% YoY but it has grown by 3.3% from the previous quarter
The quick ratio has contracted by 18% from the previous quarter but it has grown by 3.4% YoY
APRE's EPS has dropped by 128% year-on-year and by 11% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.aprea.com
Peers: HCSG ADUS AMED

Key stats

What are the main financial stats of APRE
Market
Shares outstanding
3.73M
Market cap
$13.47M
Enterprise value
-$17.52M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.51
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$109.81M
EBITDA
-$109.69M
Free cash flow
-$22.49M
Per share
EPS
-$75.13
Free cash flow per share
-$6.9
Book value per share
$7.1
Revenue per share
$0
TBVPS
$9.82
Balance sheet
Total assets
$32.02M
Total liabilities
$4.23M
Debt
$0
Equity
$26.48M
Working capital
$27.79M
Liquidity
Debt to equity
0
Current ratio
7.57
Quick ratio
7.33
Net debt/EBITDA
0.28
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-319.8%
Return on equity
-1,015.6%
Return on invested capital
N/A
Return on capital employed
-395.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

APRE stock price

How has the Aprea Therapeutics stock price performed over time
Intraday
-1.36%
1 week
6.19%
1 month
-7.43%
1 year
-77.12%
YTD
-45.46%
QTD
-18.69%

Financial performance

How have Aprea Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$109.94M
Net income
-$109.11M
Gross margin
N/A
Net margin
N/A
Aprea Therapeutics's net income has increased by 3.2% QoQ
Aprea Therapeutics's operating income has increased by 3% from the previous quarter

Growth

What is Aprea Therapeutics's growth rate over time

Valuation

What is Aprea Therapeutics stock price valuation
P/E
N/A
P/B
0.51
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
APRE's EPS has dropped by 128% year-on-year and by 11% since the previous quarter
The equity has contracted by 39% YoY but it has grown by 3.3% from the previous quarter

Efficiency

How efficient is Aprea Therapeutics business performance
The company's return on equity fell by 35% QoQ
Aprea Therapeutics's ROA has decreased by 10% from the previous quarter

Dividends

What is APRE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for APRE.

Financial health

How did Aprea Therapeutics financials performed over time
The company's total liabilities fell by 37% YoY but it rose by 32% QoQ
The company's total assets fell by 36% YoY but it rose by 6% QoQ
The debt is 100% smaller than the equity
The debt has dropped by 100% year-on-year
Aprea Therapeutics's debt to equity has shrunk by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.